OPKO Health (OPK) Announces Completion of Transition Therapeutics (TTHI) Acquisition

August 31, 2016 6:20 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

OPKO Health, Inc. (Nasdaq: OPK) announces that it has completed its previously announced acquisition of Transition Therapeutics, Inc. (Nasdaq: TTHI), by way of a plan of arrangement (the “Arrangement”) which was approved by Transition Therapeutics’ shareholders at their meeting held on August 25, 2016. Pursuant to the Arrangement, shareholders of Transition Therapeutics will receive an aggregate of approximately 6.4 million shares of OPKO common stock, or 0.1657 shares of OPKO common stock for each common share of Transition Therapeutics. The Arrangement was approved by the Ontario Superior Court of Justice in its final order dated August 29, 2016.

“We are pleased to complete the acquisition of Transition Therapeutics as it provides us with two late-stage drug candidates, each of which holds exceptional market opportunity and has direct synergies with our clinical development pipeline,” said Phillip Frost, M.D., CEO and Chairman of OPKO Health. “With the transaction complete, we look forward to advancing these promising programs to the benefit of patients suffering from Type II diabetes and obesity or certain male hormone related problems."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Management Comments, Mergers and Acquisitions

Related Entities

Definitive Agreement, PDUFA

Add Your Comment